Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Canagliflozin shows good results when compared to glimepiride in type 2 diabetes patients who were taking metformin.
Read More »New Guideline Released on Pharmacological Management of Obesity
The Endocrine Society has released a clinical practice guideline on the pharmacological management of obesity that includes recommendations on strategies for prescribing weight loss drugs.
Read More »Dr. Timothy Garvey on Qsymia and Other New Therapies for Weight Loss
Steve Freed: Let’s start out with a little background about Qsymia and Belviq. What is the FDA allowing you to treat with the drugs? Dr. Timothy Garvey: In 2012, the FDA approved two new weight loss medications. In 2014, another medication was approved. That is three new medications. We hope …
Read More »Diabetes Mellitus 101 for Cardiologists, Part 12
In this week’s Homerun Slides, we continue our discussion of incretins and then examine the benefits of adding SGLT-2 inhibitors to patient medication regimens…. To download these slides in PowerPoint (.ppt) format, use this link: Diabetes Mellitus 101 for Cardiologists, Part 12 Other sets in this series: Diabetes Mellitus 101 for Cardiologists, Part …
Read More »Investigational SGLT-2 Inhibitor Works Even with Mild Renal Loss
Patients with type 2 diabetes and mild renal impairment experienced improved glycemic control when treated with ipragliflozin… According to lead author Atsunori Kashiwagi, MD, PhD, of Kusatsu General Hospital in Shiga, among patients with mild renal impairment, patients receiving ipragliflozin had a mean decrease in HbA1c of 0.56% at 6 …
Read More »FDA Approves Xigduo XR, a New Dapagliflozin-Metformin Combination
The once-daily oral tablet is the first in the U.S. to combine the SGLT-2 inhibitor dapagliflozin with the biguanide extended-release (XR) metformin hydrochloride.. The US Food and Drug Administration (FDA) has approved a once-daily combination of dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) for the treatment of adults with …
Read More »The Role of Glutamine in Human Carbohydrate Metabolism in Kidney and Other Tissues
Glutamine is the most abundant amino acid in the human body and is involved in more metabolic processes than any other amino acid. Recent studies using isotopic and balance techniques have greatly advanced the understanding of glutamine metabolism in humans and its role in glucose metabolism in the kidney and other …
Read More »SGLT-2 Inhibitor May Reduce Blood Pressure for Type 2s
SGLT-2 inhibitor use in the management of glucose in type 2 diabetes could reduce blood pressure in patients with hypertension…. In a new study, researchers found that empagliflozin lowered blood pressure in patients with type 2 diabetes and hypertension. Hypertension affects about two-thirds of patients with diabetes. See more …
Read More »Potential of SGLT2 Inhibitors in Type 1 Diabetes
Pilot study shows that an SGLT-2 inhibitor doses of 5-mg and 10-mg were associated with significant reductions in blood glucose and total daily insulin dose…. Dapagliflozin is a member of the SGLT2 inhibitor class of diabetic medications indicated only for treatment of type 2 diabetes. Dapagliflozin helps reduce blood glucose …
Read More »Stanley Schwartz, MD: Positive Effects of More Aggressive Treatment
Dr. Stanley Schwartz relates his overwhelmingly positive experience treating patients with newer drug therapies such as GLP-1 agonists and SGLT-2 inhibitors. He explains that he will sometimes put patients, on the very first day of their visit, on these medications when their A1c’s are very high and, one month later, …
Read More »